Ascendis Pharma A/S expected to post a loss of €1.14 a share - Earnings Preview

Ascendis Pharma A/S

03/02/2025 12:21

* Ascendis Pharma A/S  ASND.OQ   ASND.O  is expected to show
a
fall in quarterly revenue when it reports  results on February 5
(estimated) for the period ending December 31 2024
    * The Hellerup Denmark-based   company is expected to report
a
19.3% decrease in revenue to €111.178 million from €137.7
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ascendis Pharma A/S is
for a
loss of €1.14 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ascendis
Pharma
A/S is $196.00​, above​ its last closing price of $130.66. ​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -1.76       -1.74      -1.72     Beat    1.2
 Jun. 30 2024  -1.34       -1.38      -1.91     Missed  -38.1
 Mar. 31 2024  -1.46       -1.50      -2.30     Missed  -53.1​
 Dec. 31 2023  -1.98       -2.03      -1.54     Beat    24
 ​​Sep.        -2.32       -2.38      -2.88     Missed  -21.1
 30 2023                                                
 Jun. 30 2023  -2.57       -2.59      -2.16     Beat    16.6​
 Mar. 31 2023  -2.65       -2.66      -1.98     Beat    25.6
 Dec. 31 2022  -2.44       -2.56      -3.70     Missed  -44.5
 This summary was machine generated February 3 at 12:21 GMT.  All
figures in euros unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)